Camizestrant Clinical Trials (2026): 10 Studies for Advanced Breast Cancer & Breast Cancer

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

10 Camizestrant clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 8 indications (including Advanced Breast Cancer & Breast Cancer) and 12,115 total planned enrollment. 3 Phase 3 Camizestrant trials and 2 Phase 2 are listed. 5 Camizestrant clinical trials are actively recruiting at 45 U.S. sites across 21 states. Most recent activity: NCT05952557 (May 2037).

Where to Participate: All Camizestrant Trial Sites in the U.S. (45 sites across 21 states)

Every actively recruiting Camizestranttrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
AZResearch SiteGilbert85234NCT06380751Map
CAResearch SiteFountain Valley92708NCT06380751Map
CAResearch SiteGlendale91206NCT06380751Map
CAResearch SiteLos Angeles90089NCT06380751Map
CAResearch SiteNewport Beach92663NCT06380751Map
COResearch SiteAurora80045NCT06380751Map
FLResearch SiteHollywood33021NCT06380751Map
FLResearch SiteJacksonville32224NCT06380751Map
ILResearch SiteArlington Heights60005NCT06380751Map
ILResearch SiteChicago60611NCT06380751Map
ILResearch SiteEvanston60201NCT06380751Map
ILResearch SiteUrbana61801NCT06380751Map
ILResearch SiteWinfield60190NCT06380751Map
MDResearch SiteSilver Spring20904NCT06380751Map
MAResearch SiteBoston02215NCT06380751Map
MIResearch SiteRoyal Oak48073NCT06380751Map
MNResearch SiteRochester55905NCT06380751Map
MOResearch SiteSaint Joseph64507NCT06380751Map
MOResearch SiteSpringfield65804NCT06380751Map
MOResearch SiteSt Louis63141NCT06188520Map
MOResearch SiteSt Louis63108NCT07427394Map
NJResearch SiteCamden08103NCT06380751Map
NYResearch SiteMineola11501NCT06380751Map
NYResearch SiteNew York10016NCT06380751Map
NYResearch SiteNew York10065NCT06380751Map
NYResearch SiteStony Brook11790NCT06380751Map
NCResearch SiteWinston-Salem27103NCT05774951Map
PAResearch SiteHershey17033NCT06380751Map
PAResearch SitePhiladelphia19104NCT06380751Map
PAResearch SitePittsburgh15215NCT06380751Map
RIResearch SiteProvidence02903NCT06188520Map
SDResearch SiteAberdeen57401NCT05774951Map
SDResearch SitePierre57501NCT05774951Map
TNResearch SiteChattanooga37404NCT06380751Map
TNResearch SiteNashville37201NCT06188520Map
TNResearch SiteNashville37203NCT06380751Map
TNResearch SiteNashville37203NCT07427394Map
TXResearch SiteHouston77030NCT06188520Map
TXResearch SiteHouston77030NCT06380751Map
TXResearch SiteHouston77054NCT06380751Map
TXResearch SiteIrving75063NCT05774951Map
TXResearch SiteSan Antonio78240NCT06380751Map
VAResearch SiteNorfolk23502NCT06380751Map
WAResearch SiteTacoma98405NCT06380751Map
WVResearch SiteMorgantown26506NCT06380751Map

Camizestrant clinical trials at a glance: phase × recruitment status

Phaserecruitingactive not recruitingcompletedTotal
P133
P1/P2112
P222
P3213

Recruiting Camizestrant clinical trials (5)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT05774951CAMBRIA-1A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyP3Breast Cancer, Early Breast Cancer4,300Mar 2023
NCT06380751EvoPAR-BR01Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerP3Advanced Breast Cancer788Aug 2024
NCT07195227CADILLACEfficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast CancerP2Hormon Receptor Positive Breast Cancer150Mar 2026
NCT07427394SERENA-1bStudy to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast CancerP2Advanced Breast Cancer24May 2026
NCT06188520CYCAD-1A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsP1/P2ER+ HER2- Advanced Breast Cancer564Dec 2023

Camizestrant clinical trials by indication

Advanced Breast Cancer (2)

NCTAcronymPhaseStatusTitle
NCT06380751EvoPAR-BR01P3recruitingSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT07427394SERENA-1bP2recruitingStudy to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Breast Cancer, Early Breast Cancer (2)

NCTAcronymPhaseStatusTitle
NCT05952557CAMBRIA-2P3active not recruitingAn Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05774951CAMBRIA-1P3recruitingA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Hormon Receptor Positive Breast Cancer (1)

NCTAcronymPhaseStatusTitle
NCT07195227CADILLACP2recruitingEfficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer

Healthy Participants (1)

NCTAcronymPhaseStatusTitle
NCT06547164AZD9833P1completedA Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants

ER+ HER2- Advanced Breast Cancer (1)

NCTAcronymPhaseStatusTitle
NCT06188520CYCAD-1P1/P2recruitingA First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

Hepatic Impairment (1)

NCTAcronymPhaseStatusTitle
NCT05790304—P1completedStudy to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

Healthy Subjects (1)

NCTAcronymPhaseStatusTitle
NCT05551897AZD9833P1completedA Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole

Ovarian Cancer (1)

NCTAcronymPhaseStatusTitle
NCT04644068PETRAP1/P2active not recruitingStudy of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Camizestrant pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

AcronymNCTPhaseStatusIndicationEnrollmentPubMed
CAMBRIA-2NCT05952557P3active not recruitingBreast Cancer, Early Breast Cancer5,511PMID 40017004
CAMBRIA-1NCT05774951P3recruitingBreast Cancer, Early Breast Cancer4,300—
EvoPAR-BR01NCT06380751P3recruitingAdvanced Breast Cancer788—
CADILLACNCT07195227P2recruitingHormon Receptor Positive Breast Cancer150—
SERENA-1bNCT07427394P2recruitingAdvanced Breast Cancer24—

All Camizestrant trials (10)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT05952557CAMBRIA-2An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)P3active not recruiting5,511AstraZenecaOct 2023
NCT05774951CAMBRIA-1A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyP3recruiting4,300AstraZenecaMar 2023
NCT06380751EvoPAR-BR01Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerP3recruiting788AstraZenecaAug 2024
NCT07195227CADILLACEfficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast CancerP2recruiting150MedSIRMar 2026
NCT07427394SERENA-1bStudy to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast CancerP2recruiting24AstraZenecaMay 2026
NCT06188520CYCAD-1A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsP1/P2recruiting564AstraZenecaDec 2023
NCT04644068PETRAStudy of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesP1/P2active not recruiting702AstraZenecaNov 2020
NCT06547164AZD9833A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female ParticipantsP1completed40AstraZenecaAug 2024
NCT05790304Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female SubjectsP1completed22AstraZenecaFeb 2023
NCT05551897AZD9833A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With ItraconazoleP1completed14AstraZenecaOct 2022

Camizestrant clinical trials: frequently asked questions

How many Camizestrant clinical trials are there?
10 Camizestrant clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants. 3 are marked completed.
Are Camizestrant clinical trials recruiting in 2026?
Yes — 5 Camizestrant trials are actively recruiting in 2026, with 45 U.S. sites across 21 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Camizestrant being studied for?
Camizestrant is being studied for Advanced Breast Cancer, Breast Cancer, Breast Cancer, Early Breast Cancer, Cervical Cancer, Colorectal Cancer and 16 more. The trials are grouped by indication on this page.
What phase is Camizestrant in?
Camizestrant clinical trials span 3 Phase 3, 2 Phase 2, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Camizestrant clinical trials?
The lead sponsor across the most Camizestrant trials is AstraZeneca, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Camizestrantas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai:

Camizestrant overviewCamizestrant evidence & publications
Camizestrant Clinical Trials (2026): 10 Studies | Hipa.ai